Melanoma Institute Australia shines at prestigious Cancer Research Awards
3 November 2018
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has won the top award for Outstanding Cancer Researcher of the Year. One of the world’s pre-eminent melanoma clinicians and researchers, Professor Long has changed the face of melanoma treatment around the world with her ground-breaking clinical trials tripling life expectancy for patients with advanced melanoma and curing a significant subset.
Fellow MIA Co-Medical Director, Professor Richard Scolyer, has been awarded The Professor Rob Sutherland AO Make a Difference Award, which is awarded in recognition of lasting impact and sustained progress to cancer care or research practice. Professor Scolyer is the world’s leading melanoma pathologist, each year receiving more than 2,000 cases for review and opinion from around the world. He recently co-edited the new WHO Classification of Skin Tumours, 4th Edition.
Also awarded were MIA’s Associate Professor Alex Menzies, who won the Outstanding Cancer Research Fellow Award with less than five years post-doctoral experience in research, and Associate Professor Anne Cust, who was awarded Outstanding Cancer Research Fellow with more than five years post-doctoral experience in research.
Associate Professor Menzies is a Medical Oncologist with research interest in clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Associate Professor Cust is an epidemiologist whose research focuses on melanoma epidemiology, prevention, early detection and survivorship and has a strong emphasis on translational outcomes.
Melanoma Institute Australia CEO Matthew Browne said it was a proud moment to see Melanoma Institute Australia’s research and clinical team centre stage at the prestigious awards night.
‘This is well deserved recognition for not only these award winners, but also the multi-disciplinary teams across MIA that work tirelessly to develop new treatments to save lives from melanoma,’ Mr Browne said.
‘My particular congratulations go to Professor Long for taking out the prestigious Outstanding Cancer Researcher of the Year Award. This is testament to her research and global thought leadership which has set the world on the path towards advanced melanoma becoming a chronic disease rather than a terminal one.
‘She was gracious in acknowledging the award was recognition of the whole team’s efforts at MIA, and particularly her long research partnership with Professor Richard Scolyer.
‘With the breakthroughs in melanoma treatment also set to revolutionise treatments for other cancers, Professor Long’s legacy will potentially impact millions across the globe.’
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.